Full-Time

Senior Financial Analyst

Corporate FP&A

Curaleaf

Curaleaf

1,001-5,000 employees

Cannabis cultivation, processing, and retailing

Compensation Overview

$94k - $104k/yr

No H1B Sponsorship

Stamford, CT, USA

In Person

Bachelor's

Category
Finance & Banking (1)
Required Skills
Power BI
Forecasting
SQL
Snowflake
Excel/Numbers/Sheets
Financial Modeling
PowerPoint/Keynote/Slides

Get referred to Curaleaf

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Finance, Accounting, Economics, Business Administration, or a related field.
  • 3–6 years of experience in FP&A, Corporate Finance, Business Analytics, Consulting, or a related analytical role.
  • Advanced Microsoft Excel skills, including financial modeling, scenario analysis, Power Query, pivot tables, and large dataset manipulation.
  • Strong PowerPoint and executive presentation skills.
  • Experience building budgets, forecasts, financial models, and executive reporting packages using planning and reporting tools such as Vena, OneStream, or similar platforms.
  • Experience with SQL, Snowflake, Power BI, Omni, or other business intelligence and data visualization tools strongly preferred.
  • Strong understanding of financial statements, budgeting, forecasting, variance analysis, and performance management.
  • Exceptional verbal and written communication skills with the ability to effectively communicate financial concepts to both financial and non-financial audiences.
  • Experience partnering with senior leadership and presenting financial results, recommendations, and insights to executive stakeholders.
  • Demonstrated ability to build strong cross-functional relationships and work effectively in a fast-paced, dynamic environment.
  • Experience supporting multi-site retail, consumer products, manufacturing, or other operationally complex organizations preferred.
  • Subject to background check per state cannabis requirements.
Responsibilities
  • Serve as a strategic finance partner to company by providing financial analysis, forecasting, reporting, and decision support for key operational, financial, and strategic initiatives.
  • Lead monthly forecasting, annual budgeting, and long-range planning processes across assigned business functions.
  • Develop, maintain, and analyze complex financial models to evaluate business performance, operational initiatives, capital investments, and growth opportunities.
  • Partner with Retail, Operations, Marketing, Shared Services, and Corporate leadership teams to identify risks, opportunities, performance improvement initiatives, and communicate financial results and recommendations to executive and C-suite stakeholders.
  • Develop, monitor, and report on key business metrics and KPIs, including retail, operational, labor, and marketing performance indicators in addition to margin and EBITDA performance.
  • Partner with Marketing leadership to evaluate campaign performance, customer acquisition trends, marketing spend effectiveness, and return on investment.
  • Produce executive-level reporting packages, variance analyses, dashboards, board materials, and presentations for senior leadership, the CFO, and other members of the executive team.
  • Drive labor planning and workforce analytics initiatives, including productivity measurement, staffing optimization, overtime analysis, and workforce forecasting.
  • Identify opportunities to automate reporting, improve data quality, and enhance financial planning and reporting processes.
Desired Qualifications
  • Experience with SQL, Snowflake, Power BI, Omni, or other business intelligence and data visualization tools strongly preferred.
  • Experience supporting multi-site retail, consumer products, manufacturing, or other operationally complex organizations preferred.

Curaleaf is a cannabis company that grows, processes, and sells cannabis products for medical and recreational use. It offers items such as tinctures, flowers, and edibles, and uses encapsulation technology to improve product absorption and effectiveness. Customers can buy at dispensaries or online, and the company also provides medical consultations and guidance services. Differentiators include its vertically integrated model (cultivation, processing, and retail) and its social responsibility efforts, such as the B NOBLE program that supports individuals with cannabis-related non-violent charges. The company’s goal is to provide reliable cannabis products and related services to a wide range of customers while advancing responsible access and advocacy through programs like B NOBLE.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wakefield, Massachusetts

Founded

2010

Get referred to Curaleaf

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $340.1 million, up 10%, with $12.5 million net income.
  • April 2026 authorized an $83 million buyback, supporting per-share results into 2027.
  • August 11, 2026 Aurora bid targets EU medical synergies and about $40 million savings.

What critics are saying

  • June 30, 2026 debt was $611.5 million against $107 million cash, squeezing optionality.
  • Aurora’s board can reject Curaleaf’s $4 bid, wasting management attention through late 2026.
  • New Jersey appealed Curaleaf’s labor-peace win, while May 2026 health-claims class actions persist.

What makes Curaleaf unique

  • July 2026 Spain registrations made Curaleaf first standardised medical cannabis supplier there.
  • Four 20 Pharma gives Curaleaf EU-GMP distribution across Germany and select European markets.
  • Florida scale matters: Curaleaf opened its 75th Florida dispensary on August 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

Life Insurance

Disability Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 18th, 2026
Curaleaf launches $4 hostile bid for Aurora Cannabis to access EU medical market

Curaleaf has formally launched its hostile takeover bid for Aurora Cannabis, offering $4 per share directly to shareholders. The offer represents a 45% premium on Aurora's 30-day average share price from 10 August, before Curaleaf announced its intentions. The proposed deal would create a combined company with a $3 billion market cap. Curaleaf projects approximately $40 million in annual cost synergies from the merger. The acquisition aims to give Curaleaf access to EU medical cannabis export markets, particularly Germany. Aurora possesses EU-GMP cultivation capacity that meets strict German import standards. Federal restrictions make direct cannabis exports challenging for US firms like Curaleaf. Curaleaf CEO Boris Jordan said initial friendly discussions with Aurora CEO Miguel Martin earlier this summer stalled, prompting the direct shareholder approach. Aurora's board has formed a special committee to review the offer.

PR Newswire
Aug 5th, 2026
Curaleaf reports $340M Q2 revenue with 10% growth and $12M net income

Curaleaf Holdings reported second quarter 2026 revenue of $340 million, representing 10% year-over-year growth driven by domestic and international segments that grew 7% and 26%, respectively. International revenue reached $51 million. The cannabis company posted net income of $12 million and adjusted EBITDA of $70 million, reflecting a 21% margin. Gross profit margin stood at 50%. Chairman and CEO Boris Jordan said the results demonstrate the company's "Built for Growth" strategy is gaining traction. He noted this marks the second consecutive quarter of domestic year-over-year growth. Curaleaf ended the quarter with $107 million in cash and $611.5 million in outstanding debt. The company invested $32.9 million in capital expenditures during the six-month period, focused on facility upgrades and automation.

PR Newswire
Jul 29th, 2026
Curaleaf opens 75th Florida dispensary, expanding US footprint to 167 locations

Curaleaf Holdings has opened its 75th dispensary in Florida, located in Boynton Beach. The cannabis retailer now operates 167 locations nationwide, with Florida representing nearly half of its retail footprint. The new store at 3575 W. Boynton Beach Boulevard is the company's sixth Florida opening this year. It offers medical cannabis products including Anthem pre-rolls, Dark Heart ultra-premium flower, and Select vaping products. Boris Jordan, chairman and CEO, said the opening reinforces Curaleaf's commitment to expanding access to cannabis products across Florida. A grand opening celebration is scheduled for 31 July and 1 August, featuring special promotions and giveaways. The dispensary operates 9:00 to 20:30 Monday through Saturday, and 10:00 to 18:00 on Sunday.

Yahoo Finance
Jul 13th, 2026
Curaleaf becomes first company to register standardised cannabis preparations in Spain

Curaleaf Holdings has become the first company to secure registration for standardised cannabis preparations in Spain under the country's new regulatory framework, Royal Decree 903/2025. Spain's medicines agency AEMPS approved two preparations — THC-dominant and CBD-dominant — developed by Curaleaf's Spanish manufacturing subsidiary. The registrations enable supply to hospital pharmacies, where the preparations can be used in magistral formulas under medical prescription. Royal Decree 903/2025, approved in October 2025, establishes Spain's regulatory framework for medicinal cannabis, setting production and quality standards. Curaleaf operates an EU-GMP certified manufacturing facility and R&D laboratory in Alicante. The company secured Spain's first licence to process medicinal cannabis derivatives for commercial distribution in May 2020. The preparations are expected to become available to patients through hospital pharmacies as Spain's regulated system develops.

PR Newswire
May 8th, 2026
Curaleaf opens two new Florida medical dispensaries, expanding state footprint to 73 locations

Curaleaf Holdings has opened two new medical cannabis dispensaries in Florida, located in Jacksonville Beach and Fernandina Beach. The openings bring the company's Florida dispensary count to 73 and its nationwide total to 165 locations. The Jacksonville Beach location sits on Beach Boulevard along US Route 90, whilst the Fernandina Beach dispensary is positioned on South 8th Street along Florida State Road 200. Both stores offer Curaleaf's Florida-exclusive products, including Reef flower, Grassroots flower and Select Briq 2. Chairman and CEO Boris Jordan said the expansion reflects the company's strategy to strengthen its presence in Florida's medical cannabis market. Grand opening celebrations will take place at both locations in May, featuring live entertainment, promotions and giveaways.